Clinical Trials on Melanoma (Skin)

Total 51925 results

ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy

Melanoma (Skin)
NYU Langone Health
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States
San Diego Pacific Oncology & Hematology Associates

Unknown

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

Melanoma (Skin)

United States
University Medical Center Groningen

Unknown

Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma

Melanoma (Skin)

Netherlands
Dana-Farber Cancer Institute

Completed

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

Melanoma (Skin)

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

United States
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

Melanoma (Skin)

Italy, France, Spain, Switzerland, United Kingdom, Belgium, Australia, Norway, Poland, Finland, Netherlands, Germany, Israel, Denmark, Serbia, Estonia, Portugal, Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Celgene

Active, not recruiting

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Metastatic Melanoma | Melanoma and Other Malignant Neoplasms of Skin

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Replimune Inc.

Recruiting

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Cancer | NSCLC | Melanoma (Skin) | Microsatellite Instability | Cutaneous Melanoma | Mismatch Repair Deficiency | Non-melanoma Skin Cancer

United States, Spain, France, United Kingdom, Germany
Fudan University

Recruiting

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

China
Memorial Sloan Kettering Cancer Center
Iovance Biotherapeutics, Inc.

Recruiting

Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma

Melanoma | Metastatic Melanoma | Metastatic Uveal Melanoma | Uveal Melanoma

United States
Roswell Park Cancer Institute

Recruiting

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7

United States
AI Labs Group S.L
Hospital de Basurto; Osakidetza; Hospital de Cruces; Servicio Vasco de Salud Osakidetza...

Recruiting

Clinical Validation Study of an AI-based CAD System for Early Non-Invasive Detection of Cutaneous Melanoma (LEGIT_MC_EVCDA)

Melanoma | Melanoma, Skin

Spain
Centre Hospitalier Universitaire de Nice

Recruiting

Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma (MEL-META)

Melanoma (Skin)

France
East and North Hertfordshire NHS Trust
King's College London

Recruiting

Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics (PRIMM)

Melanoma (Skin)

United Kingdom
University of Sydney
Melanoma and Skin Cancer Trials Limited

Completed

Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. (MEL-SELF)

Melanoma (Skin)

Australia
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

United States
University of Utah

Completed

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

Melanoma (Skin)

United States
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; Dutch...

Active, not recruiting

Melanoma Patients Immunized With Natural DenDritic Cells (MIND-DC)

Melanoma (Skin)

Netherlands
NCIC Clinical Trials Group

Completed

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Melanoma (Skin)

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Melanoma (Skin)

United States
Centre Hospitalier Universitaire, Amiens

Unknown

New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy (SkinTher)

Melanoma (Skin)

France
AVAX Technologies

Terminated

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States
Cancer Trials Ireland

Completed

Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

Melanoma (Skin)

Ireland
University of Colorado, Denver
National Cancer Institute (NCI)

Completed

Irofulven in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Hackensack Meridian Health
National Cancer Institute (NCI)

Withdrawn

High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Withdrawn

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
Yale University; University of New Mexico

Completed

Differential Risks for Melanoma: p16 and DNA Repair

Melanoma | Skin Melanoma

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Stage IIIB Cutaneous Melanoma AJCC v7

United States, Canada
Leeds Cancer Centre at St. James's University Hospital

Unknown

Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma

Melanoma (Skin) | Hereditary Multiple Melanoma

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); GlaxoSmithKline; Merck Sharp & Dohme LLC; National...

Active, not recruiting

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Metastatic Melanoma | Melanoma and Other Malignant Neoplasms of Skin

United States
Melanoma and Skin Cancer Trials Limited
Monash University

Completed

Improving Skin Cancer Management With Artificial Intelligence (04.17 SMARTI) (SMARTI)

Skin Cancer | Melanoma (Skin)

Australia
Philogen S.p.A.

Completed

Intratumoral Administration of L19IL2/L19TNF

Malignant Melanoma, Skin

Italy
Genzyme, a Sanofi Company

Unknown

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Delcath Systems Inc.

No longer available

Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

Ocular Melanoma | Cutaneous Melanoma | Metastatic Liver Cancer

United States
Ohio State University Comprehensive Cancer Center

Completed

The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients

Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Miltenyi Biomedicine GmbH
DLR German Aerospace Center

Terminated

MB-CART20.1 Melanoma

Melanoma (Skin)

Germany
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Vaccinex Inc.

Terminated

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Biocad

Recruiting

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma (NEO-MIMAJOR)

Melanoma (Skin) | Melanoma Stage III

Russian Federation, Belarus
National Cancer Institute (NCI)

Active, not recruiting

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Metastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...

United States, Canada, Ireland
National Cancer Institute (NCI)

Completed

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage... and other conditions

United States

Clinical Trials on Melanoma (Skin)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations